- 4.4Impact Factor
- 8.8CiteScore
- 21 daysTime to First Decision
Special Issues
Cancers publishes Special Issues to create collections of papers on specific topics, with the aim of building a community of authors and readers to discuss the latest research and develop new ideas and research directions. Special Issues are led by Guest Editors, who are experts on the topic and all Special Issue submissions follow MDPI's standard editorial process.
The journal’s Editor-in-Chief and/or designated Editorial Board Member will oversee Guest Editor appointments and Special Issue proposals, checking their content for relevance and ensuring the suitability of the material for the journal. The papers published in a Special Issue will be collected and displayed on a dedicated page of the journal’s website. Further information on MDPI's Special Issue polices and Guest Editor responsibilities can be found here. For any inquiries related to a Special Issue, please contact the Editorial Office.
Nanomedicine for Cancer Treatment
Deadline: 31 July 2026
Current Applications and Cutting-Edge Innovations in Neuroendoscopy for Oncological Neurosurgery: Where Are We and Where Are We Going?
Deadline: 31 July 2026
Decoding the Tumor Microenvironment: Immune Cell–Tumor Interplay in Breast Cancer
Deadline: 31 July 2026
Novel Insights into Glioblastoma and Brain Metastases (2nd Edition)
Deadline: 31 July 2026
Biologic Advancements in Childhood and Adolescent Cancers: From Disease Mechanisms to Precision Therapies
Deadline: 31 July 2026
Molecular Mechanisms of Resistance to Cancer Therapies
Deadline: 31 July 2026
Microsatellite Instability in Colorectal Cancer
Deadline: 31 July 2026
Cancer After Kidney Transplant
Deadline: 31 July 2026
Pheochromocytoma and Paraganglioma: Molecular Insights and Clinical Frontiers
Deadline: 31 July 2026
Surgical and Non-Surgical Convergence in Hepatocellular Carcinoma
Deadline: 31 July 2026
Epigenetics: A New Approach to Cancer Therapy
Deadline: 31 July 2026
Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) in Patients with Cancers
Deadline: 31 July 2026
of 261

